

Certificate of Analysis for NR-45927

Staphylococcus hominis subsp. novobiosepticus, Strain NRS122

Catalog No. NR-45927

Product Description: *Staphylococcus hominis* (*S. hominis*) subsp. *novobiosepticus*, strain NRS122 was isolated in April 2002 from a 42-year-old male inpatient in Maryland, USA.

Lot¹: 70011781 Manufacturing Date: 12JAN2018

| TEST | SPECIFICATIONS | RESULTS |
|---|--|---|
| Phenotypic Analysis | | |
| Cellular morphology | Gram-positive cocci | Gram-positive cocci |
| Colony morphology ² | Report results | Circular, convex, entire, smooth and cream (Figure 1) |
| Motility (wet mount) | Report results | Non-motile |
| Hemolysis ³ | Report results | β-hemolytic |
| Biochemical characterization | | |
| Catalase | Positive | Positive |
| Coagulase ⁴ | Report results | Negative |
| VITEK® 2 Compact (GP card) | S. hominis subsp. novobiosepticus (≥ 89%) | S. hominis (low discrimination) ⁵ |
| VITEK® MS (MALDI-TOF) | S. hominis subsp. novobiosepticus | S. hominis subsp. hominis (99.9%) ⁶ |
| Antibiotic Susceptibility Profile ⁷ VITEK® (AST-GP71 card) | | |
| Beta-lactamase ⁸ | Report results | Positive |
| Cefoxitin screen | Report results | Positive |
| Benzylpenicillin | Resistant | Resistant (≥ 0.5 µg/mL) |
| Oxacillin | Resistant | Resistant (≥ 4 μg/mL) |
| Gentamicin | Sensitive | Sensitive (= 1 µg/mL) |
| Ciprofloxacin | Resistant | Resistant (≥ 8 µg/mL) |
| Levofloxacin | Report results | Resistant (≥ 8 µg/mL) |
| Moxifloxacin | Report results | Resistant (= 4 µg/mL) |
| Clindamycin (inducible resistance) | Report results | Negative |
| Erythromycin | Resistant | Resistant (≥ 8 µg/mL) |
| Clindamycin | Resistant | Resistant (≥ 8 µg/mL) |
| Quinupristin/dalfopristin | Sensitive | Sensitive (= 0.5 µg/mL) |
| Linezolid | Sensitive | Sensitive (= 2 µg/mL) |
| Daptomycin | Susceptible | Susceptible (≤ 0.25 µg/mL) |
| Vancomycin | Sensitive | Sensitive (= 1-2 µg/mL) |
| Minocycline | Report results | Sensitive (≤ 0.5 µg/mL) |
| Tetracycline | Report results | Sensitive (= 2 µg/mL) |
| Tigecycline | Report results | Sensitive (≤ 0.12 μg/mL) ⁹ |
| Nitrofurantoin | Report results | Sensitive (≤ 16 μg/mL) |
| Rifampicin | Report results | Sensitive (= 1 µg/mL) |
| Trimethoprim/sulfamethoxazole | Sensitive | Sensitive (≤ 10 µg/mL) |
| Etest® antibiotic test strips10 | | |
| Vancomycin | Sensitive | Sensitive (= 3 µg/mL) |
| Teicoplanin | Sensitive | Sensitive (= 1.5 µg/mL) |
| Genotypic Analysis | | |
| Sequencing of 16S ribosomal RNA gene | ≥ 99% sequence identity to <i>S. hominis</i> | 99.9% sequence identity to <i>S. hominis</i> |
| (~ 760 base pairs) | subsp. novobiosepticus type strain | subsp. novobiosepticus type strain |
| | (GenBank: PPQX01000061.1) | (GenBank: PPQX01000061.1) ¹¹ |
| Digital DNA-DNA hybridization (dDDH) ¹² | ≥ 70% for species identification | S. hominis subsp. novobiosepticus |
| | | (83.0%) ^{13,14} |
| Purity (post-freeze) ¹⁵ | Consistent with expected colony | Consistent with expected colony |
| i unity (post-ineeze) | morphology | morphology |
| Viability (post-freeze) ² | Growth | Growth |
| , , | | |

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



Certificate of Analysis for NR-45927

SUPPORTING INFECTIOUS DISEASE RESEARCH

- 1S. hominis subsp. novobiosepticus, strain NRS122 was deposited to BEI Resources as part of the NARSA collection. NR-45927 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles which were grown 1 day at 37°C in an aerobic atmosphere to produce this lot.
- ²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar
- ³1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood
- ⁴1 day at 37°C in rabbit serum with 0.15% EDTA (Coagulase Plasma BBL™ 240827)
- ⁵The VITEK® 2 Compact (GP card) performed in triplicate could not distinguish between *S. hominis* subsp. *novobiosepticus* and *S. hominis* subsp. *hominis* based on the D-amygdalin, L-pyrrolydonyl-arylamidase, D-mannose, D-trehalose and bacitracin resistance test results. For additional information on the differentiating characteristics of *S. hominis* subsp. *novobiosepticus* and *S. hominis* subsp. *hominis*, please refer to Kloos, W. E., et al. "*Staphylococcus hominis* subsp. *novobiosepticus* subsp. nov., a Novel Trehalose- and N-Acetyl-D-Glucosamine-Negative, Novobiocin- and Multiple-Antibiotic-Resistant Subspecies Isolated from Human Blood Cultures." Int. J. Syst. Bacteriol. 48 (1998): 799-812. PubMed: 9734034.
- ⁶The VITEK[®] MS cannot differentiate between *S. hominis* subsp. *novobiosepticus* and *S. hominis* subsp. *hominis*, but the result is reported as *S. hominis* subsp. *hominis*.
- ⁷Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
- ⁸The production of beta-lactamase was detected using a Cefinase™ Paper Disc (BBL™ 231650).
- ⁹MIC Interpretation Guideline: EUCAST Version 4.0 (2014)
- ¹⁰1 day at 37°C in an aerobic atmosphere on Mueller Hinton agar
- ¹¹Also consistent with *S. hominis* subsp. *hominis*
- ¹²Relatedness between bacterial strains has traditionally been determined using DDH. For additional information, refer to Auch, A.F., et al. "Digital DNA-DNA Hybridization for Microbial Species Delineation by Means of Genome-to-Genome Sequence Comparison." <u>Stand. Genomic Sci.</u> 2 (2010): 117-134. PubMed: 21304684. *S. hominis* subsp. *novobiosepticus*, strain CCUG 42399^T (GenBank: PPQX01.1) was used for dDDH analysis.
- ¹³The whole genome of *S. hominis* subsp. *novobiosepticus* was sequenced using the Illumina® MiSeq® system and was assembled and analyzed with CLC Genomics Workbench.
- ¹⁴Originally deposited as S. epidermidis and updated to S. hominis subsp. novobiosepticus following dDDH analysis
- ¹⁵Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with 5% CO₂ on Tryptic Soy agar.



Figure 1: Colony Morphology

/Heather Couch/ Heather Couch

01 MAY 2019

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898